Skip to main content
Equibles

TAK · Takeda Pharmaceutical Co Ltd · Financials

Track TAK — free

Use TAK with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TAK.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$19.76 +0.09 (+0.46%)
Rebalance outlook locked
Market Cap
$62.84B
Shares
3.19B
Volume · Oct 16 2.83M Avg daily vol (3M) 2.97M

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Pull these statements through the financial statements API or MCP →
Revenue
4.51T -1.7%
FY2026 Revenue FY2017–FY2026
Net Income
-152.39B -241.2%
FY2026 Net Income FY2017–FY2026
Gross Margin
65.12% -0.4pp
FY2026 Gross Margin FY2017–FY2026
Operating Margin
0.14% -7.3pp
FY2026 Operating Margin FY2017–FY2026
Diluted EPS
-96.75 -243.9%
FY2026 Diluted EPS FY2017–FY2026
Operating Cash Flow
1.04T -1.5%
FY2026 Operating Cash Flow FY2017–FY2026

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics
Annual Quarterly
Line Item FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017
JPY 4.51T 4.58T 4.26T 4.03T 3.57T 3.2T 3.29T 2.1T 1.77T 1.73T
JPY 1.57T 1.58T 1.43T 1.24T 1.11T 994.31B 1.09T 651.73B 495.92B 558.76B
JPY 675.92B 730.23B 729.92B 633.33B 526.09B 455.83B 492.38B 368.3B 325.44B 312.3B
JPY 1.08T 1.1T 1.05T 997.31B 886.36B 875.66B 964.74B 717.6B 628.11B 619.06B
JPY 721.13B 761.4B 728B 664.4B 583.15B 559.67B 583.65B 247.69B 182.13B 171.43B
JPY 6.22B 342.59B 214.08B 490.51B 460.84B 509.27B 100.41B 237.69B 241.79B 155.87B
JPY 357.57B 210.07B 219.85B 169.7B 166.61B 248.63B 165.01B 83.29B 31.93B 23.25B
JPY -142.36B 175.08B 52.79B 375.09B 302.57B 366.24B -60.75B 127.61B 217.21B 143.35B
JPY 9.77B 66.94B -91.41B 58.05B 72.41B -9.94B -105.04B -7.47B 30.5B 27.83B
JPY -152.39B 107.93B 144.07B 317.02B 230.06B 376.01B 44.24B 135.19B 186.89B 114.94B
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2017–FY2026: 259.17B in buybacks, 2.46T in dividends.

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balanceAs ofAmountSource
Bonds issued 2026-03-31 JPY 4,656,812,000,000 20-F filed 2026-06-17
Borrowings 2026-03-31 JPY 4,881,837,000,000 20-F filed 2026-06-17
Related accounting measures — not additional borrowing

Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.

Current borrowings, including current portion of noncurrent borrowings
JPY 512,157,000,000
Noncurrent long-term borrowings
JPY 4,369,681,000,000
Lease liabilities 2026-03-31 JPY 594,520,000,000 20-F filed 2026-06-17
Loans received 2026-03-31 JPY 225,026,000,000 20-F filed 2026-06-17
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.

Key facts CIK 1395064 CUSIP 874060205 13F (30d) 59 filings 44 filers Visit website Investor relations